eCase Study Videos
Regeneron Genetics Center researchers and their colleagues identified a number of protective gene-trait associations from the UK Biobank dataset.
While early-stage Pseudomonas aeruginosa sinus infections were marked by selection for aggregating forms of the bug, genetic drift and genome degradation arose later in infection.
Biotech company GeneTether, which develops technologies to increase the correction efficiency of targeted genome editing technologies, has appointed Roland Boivin as CEO, Jean Jen as CFO, and Peter Sampson as vice president of R&D.
The IMTAC discovery platform is at the center of BridGene's efforts to identify new drugs and new targets for current drugs.
The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.
New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.
The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.
In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.
The San Diego-based firm said the funding will help it develop three key steps in its chemistry: incorporation of nucleotides, deblocking, and cleanup.
Vibrent has developed a digital research platform allowing individual investigators and other twin registries to collaborate on longitudinal studies.
Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.
Inivata's InVisionFirst-Lung and RaDaR assays will support studies of the use of liquid biopsies in early and minimal residual disease detection.
At the ASHG annual meeting this week, a Newcastle University researcher described efforts to find de novo mutations behind oligozoospermia or azoospermia.
The RT-PCR-based CovidNow SARS-CoV-2 test may be used with upper respiratory specimens, as well as self-collected anterior nasal specimens.
The investment bank said the company is well positioned to take shares from reference labs and other point-of-care testing companies.